New Frontiers in the Treatment and Management of Relapsed/Refractory Multiple Myeloma: A Closer Look at the Role of New and Emerging Therapies

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from November 1, 2020 to March 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Oncopeptides and Sanofi Genzyme

Description:
Multiple Myeloma (MM) accounts for 10% of hematologic malignancies. In 2020, it is estimated that MM will be responsible for 12,960 new deaths and 32,110 new cases. Multiple myeloma is a systemic malignancy of plasma cells that is highly treatable but rarely curable. It is potentially curable when it presents as a solitary plasmacytoma of bone or as an extramedullary plasmacytoma. The median survival in the prechemotherapy era was about 7 months. After the introduction of chemotherapy, prognosis improved significantly with a median survival of 24 months to 30 months and a 10-year survival of 3%. There are several novel options currently undergoing late stage clinical trials or regulatory review for relapsed or refractory multiple myeloma that have shown great promise in their ability to improve clinical outcomes. It is important that medical directors, oncologists, nurse case managers and other healthcare professionals are brought up to date on these emerging therapies and how these options might be integrated into evolving treatment paradigms in the management of relapsed/refractory multiple myeloma treatment.

Multiple Myeloma is staged by estimating the myeloma tumor cell mass on the basis of the amount of monoclonal (or myeloma) protein (M protein) in the serum and/or urine, along with various clinical parameters, such as the hemoglobin and serum calcium concentrations, the number of lytic bone lesions, and the presence or absence of renal failure. The stage of the disease at presentation is a strong determinant of survival. Treatment selection is influenced by the age and general health of the patient, prior therapy, and the presence of complications of the disease. Despite treatment advances in the last several years, multiple myeloma remains a disease with poor long-term survival as it is currently incurable and all patients will eventually relapse, underlining the need for new therapies. Fortunately for patients with MM, new options are currently undergoing late stage clinical trials or regulatory review, including novel peptide-drug conjugates that rapidly deliver a cytotoxic payload into myeloma cells, which appear to improve patient outcomes at a significant rate. It is critical that medical directors, oncologists, pharmacy directors and nurses are updated about these novel therapies.

Upon completion of this activity, participants will be able to:

  • Differentiate the mechanism of action, safety, and efficacy profiles of new and emerging therapies for the treatment of relapsed/refractory multiple myeloma

  • Assess the role of new and emerging anti-CD38 monoclonal antibodies and lipophilic peptide-conjugated alkylators in the relapsed/refractory multiple myeloma treatment paradigm

  • Understand best practices and strategies for the selection of therapies for relapsed/refractory MM based on patient risk stratification, prior therapeutics regimens, and other clinical considerations

  • Explore managed care considerations of new and emerging therapies by exploring where these agents fit into current relapsed/refractory multiple myeloma management paradigm

  • Identify adverse events associated with new and emerging therapies in relapsed/refractory multiple myeloma, and select appropriate strategies to help ensure patient treatment adherence and optimal quality of life

  • Examine factors driving the discrepancy between real-world effectiveness of relapsed/refractory multiple myeloma agents and clinical trial efficacy outcomes

     

Faculty: Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute

Disclosure:

Dr. Anderson serves as a consultant for Bristol-Myers Squibb, Gilead Sciences, Janssen, Precision Biosciences, Sanofi, Takeda, and Tolero. He owns stock in C4 Therapeutics and Oncopeptides. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Oncopeptides and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue